+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of AZD6234 as an additional treatment alongside incretin-based therapies in adults who are overweight or have obesity with at least one weight-related health condition, with or without Type 2 Diabetes Mellitus. This Phase III global study will compare how well AZD6234 works against a placebo by measuring changes in body weight over 68 weeks. Participants will be randomly assigned to receive either AZD6234 or a matching placebo, both given as weekly injections under the skin. These treatments will be added to their stable dose of existing incretin-based medications. The study is designed to monitor participants for 68 weeks of treatment to assess the impact on body weight and related health measures. During the study, participants will undergo regular assessments including body weight measurements, waist circumference, blood pressure, blood tests for triglycerides and HbA1c, and evaluation of weight loss milestones. Safety and effectiveness will be closely monitored throughout the treatment period, which lasts about 68 weeks. The study aims to provide detailed information on how AZD6234 affects weight and metabolic health in this population.

Age: 18Years +All GendersPhase 3
96 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
C

Actively Recruiting

Researchers are investigating the effects of two types of nerve blocksfemoral triangle block FTB and adductor canal block ACBon early quadriceps muscle function after total knee arthroplasty TKA. The study aims to find out if FTB leads to more early quadriceps weakness compared to ACB when both are used with a standardized multimodal pain relief plan. This randomized, double-blind trial involves adult patients undergoing primary unilateral TKA to better understand postoperative motor function and pain management.

Age: 20Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the Double-effect kissing balloon technique W-KBT using Perfusion balloon PB and Drug coated balloon DCB in patients with left main coronary artery disease LMD who have left circumflex artery LCx ostium stenosis. This prospective, observational, multi-center study focuses on patients with stable angina, non-ST-elevation myocardial infarction, or unstable angina who require percutaneous coronary intervention PCI. Patients who meet the selection criteria will receive PCI with W-KBT following crossover stenting for LMT-LAD direction, proximal optimization technique POT, and conventional kissing balloon technique C-KBT as part of usual care. Approximately 280 participants aged 18 and older will be enrolled across 17 sites in Japan. The study will monitor patients through hospital discharge and for 12 months afterward during routine clinical practice. Participants will be followed to assess procedure success during PCI and major adverse cardiovascular events MACE within 12 months. Additional measures include time to ST-change from DCB inflation, total DCB inflation time, changes in blood pressure and heart rate, use of vasopressors or mechanical support after W-KBT, and incidence of ischemia-driven revascularization at the LCx ostium. Data will be collected to evaluate the efficacy and safety of this treatment approach over the year following the procedure.

Age: 18Years +All Genders
32 locations